Overall response Rates2,3
CLINICAL DATA
In a Phase III clinical trial, DACOGEN® (decitabine) for Injection
plus supportive care was proven superior to supportive care alone in treating patients
with myelodysplastic syndromes (MDS).
Patients who responded to DACOGEN plus supportive care vs supportive care alone
had:
- Better overall improvement rates
- Transfusion independence2,3
Visit other pages in this section to learn more about the studies and what their
results may mean to you.
References
DACOGEN is indicated for treatment of patients with myelodysplastic syndromes (MDS),
including previously treated and untreated, de novo, and secondary MDS of all FAB
subtypes (RA, RARS, RAEB, RAEB-t, CMML) and Intermediate-1, Intermediate-2, and
High-Risk IPSS groups.
DACOGEN may cause fetal harm when administered to a pregnant woman. Women of childbearing
potential should be advised to avoid becoming pregnant while using DACOGEN. Men
should be advised not to father a child while receiving treatment with DACOGEN,
and for 2 months afterwards. The most commonly occurring adverse reactions include
neutropenia, thrombocytopenia, anemia, fatigue, pyrexia, nausea, cough, petechiae,
constipation, diarrhea, and hyperglycemia.
DACOGEN is available by prescription only. Please see the important product information
for DACOGEN for more information. This site does not contain everything that is
known about DACOGEN. If you would like to know more, talk to your healthcare professional.